Changing pills to a more user-friendly formulation can increase patient compliance, brand loyalty, and extend IP exclusivity, says CMO Hermes in an exclusive podcast.

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth the cost.

Catalent has announced two new softgel solutions as it adds greater versatility to its Advanced Technologies Business Unit.

In the war against counterfeits, regulators have concentrated on serialisation and ePedigree and missed an opportunity on product authentication, according to AlpVision.

Excipient firms that skip lot testing or use alternative analysis methods should justify their decisions according to a new COA guide issued by IPEC Americas.

Risk-based monitoring for clinical trials was a hot topic at this year’s PCT Europe thanks to recent draft guidances from the FDA and the EMA.

The positive impact drug industry demand for quality is having on the fine chemicals sector was evident at industry trade show CPhI last month according to expert Jan Ramakers.

CMO Cobra Biologics says North America is an obvious place to look at for a facility acquisition.

Catalent says making its technology available to industry will not affect its competitive edge.

Bend Research is “actively” hunting new partnerships similar to its recent alliance with Dow.